Novel Preclinical Studies with MabVax Therapeutics' HuMab-5B1 Antibody and HuMab-GD2 Antibodies Presented at the 2017 World Molecular Imaging Congress

Tuesday, October 3, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Favorable Results in Both Studies Encourage Continuing Development for Better Patient Treatment Options



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook